Diseases of Globalization

McMurray, Christine; Smith, Richard J.H.

doi:10.4324/9781315071718

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sacubitrilat (LBQ657), an active metabolite of sacubitril, does not inhibit aminopeptidase P so the risk of angio-oedema was expected to be lower than with omapatrilat (Hegde 2011; Jhund 2016; Marques da Silva 2017). Given twice daily, sacubitril/valsartan causes neprilysin and RAAS inhibition over a 24-hour period (McMurray 2013). The systemic exposure delivered by sacubitril/valsartan 97 mg/103 mg (200 mg LCZ696) is equivalent to 160 mg of valsartan and a er this dosage neprilysin is almost completely inhibited for up to 12 hours (Hegde 2011;Jhund 2016;Marques da Silva 2017).…”

Section: Cochrane Database Of Systematic Reviewsmentioning

confidence: 99%

LCZ696 (sacubitril/valsartan) for patients with heart failure

Hernandez

Pasupuleti²,

Banach

et al. 2020

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:To assess benefits and harms of first-in-class angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (LCZ696) as compared to angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in chronic heart failure (HF) patients with either reduced, mid-range, or preserved ejection fraction.LCZ696 (sacubitril/valsartan) for patients with heart failure (Protocol)

show abstract

Section: Cochrane Database Of Systematic Reviewsmentioning

confidence: 99%

LCZ696 (sacubitril/valsartan) for patients with heart failure

Hernandez

Pasupuleti²,

Banach

et al. 2020

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

The association between motor vehicle injuries and health-related quality of life: a longitudinal study of a population-based sample in the United States

et al. 2013

View full text Add to dashboard Cite

show abstract

Health Impact Assessment of Connected and Autonomous Vehicles in San Francisco, Bay Area

Pourrahmani

Jaller

Maizlish

et al. 2020

Transportation Research Record: Journal of the Transportation R

View full text Add to dashboard Cite

This paper presents the potential human health impacts from connected and autonomous vehicles (CAVs) in the San Francisco, Bay Area, U.S. The study concentrates on impacts derived from CAVs’ outcomes on travel demand, safety, and environmental emissions. The paper combines travel modeling practices, critical literature review, and the authors’ expert inference, to quantify the human health impacts using the Integrated Transport and Health Impacts Model (ITHIM). Specifically, ITHIM estimates impact considering changes in travel demand, level of physical activity, emissions, and safety features. This study estimates a 10% increase in car travel mileage and an 11% decrease in walk/bike trip mode share at the presence of CAVs; a 70%–90% crash reduction because of safer CAVs; and significant emission reduction by several CAV-enabled mechanisms such as eco-driving (over 30% CO2 emission reduction) and engine performance adjustment (over 20% CO2 emission reduction). The health impact assessments show significant opportunities for road traffic injury reductions (annual saving of more than 300 deaths and 14,000 life years). However, reduced physical activity because of the mode shift to the car could cause negative health outcomes (increased annual deaths and disability-adjusted life years (DALYs) by more than 30–60 and 700–900, respectively). A set of (active transport [AT] and vehicle electrification) scenarios were developed that could mitigate the potential health-related risks and evaluated their effectiveness. The results show enormous benefits from 50% increased travel-related physical activity which offset the CAV health drawbacks and generates additional benefits by preventing premature deaths and saving life years.

show abstract

Diseases of Globalization

Cited by 4 publications

References 0 publications

LCZ696 (sacubitril/valsartan) for patients with heart failure

LCZ696 (sacubitril/valsartan) for patients with heart failure

The association between motor vehicle injuries and health-related quality of life: a longitudinal study of a population-based sample in the United States

Health Impact Assessment of Connected and Autonomous Vehicles in San Francisco, Bay Area

Contact Info

Product

Resources

About